Femasys Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 3/6

Femasys har ett totalt eget kapital på $6.0M och en total skuld på $5.1M vilket ger sin skuldsättningsgrad till 84.9%. Dess totala tillgångar och totala skulder är $15.6M respektive $9.6M.

Viktig information

84.9%

Skuldsättning i förhållande till eget kapital

US$5.07m

Skuld

Räntetäckningsgrad	n/a
Kontanter	US$7.61m
Eget kapital	US$5.97m
Summa skulder	US$9.62m
Totala tillgångar	US$15.59m

Nya uppdateringar om finansiell hälsa

Recent updates

Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way?

Feb 16

Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?

Oct 31

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Jul 05

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Apr 03

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Sep 27

Femasys commercially launches Femcerv for cervical cancer screening

Sep 29

Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Aug 10

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

May 22

Femasys: Revolutionizing Female Reproduction

Jul 16

Analys av finansiell ställning

Kortfristiga skulder: FEMY s kortfristiga tillgångar ( $11.3M ) överstiger dess kortfristiga skulder ( $2.9M ).

Långfristiga skulder: FEMY s kortfristiga tillgångar ( $11.3M ) överstiger dess långfristiga skulder ( $6.7M ).

Skuld till eget kapital Historik och analys

Skuldnivå: FEMY har mer kontanter än sin totala skuld.

Minska skulden: Otillräckliga data för att avgöra om FEMY s skuldsättningsgrad har minskat under de senaste 5 åren.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: FEMY har mindre än ett år av cash runway baserat på dess nuvarande fria kassaflöde.

Prognos Cash Runway: FEMY har mindre än ett år av kontanter om det fria kassaflödet fortsätter att minska med historiska takter på 19.2 % varje år

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/04 01:31
Aktiekurs vid dagens slut	2025/03/04 00:00
Intäkter	2024/09/30
Årlig intjäning	2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Femasys Inc. bevakas av 4 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Keay Nakae	Chardan Capital Markets, LLC
Emily Bodnar	H.C. Wainwright & Co.
Catherine Novack	JonesTrading Institutional Services, LLC

Femasys Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 3/6

Viktig information

Nya uppdateringar om finansiell hälsa

Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way?

Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

Recent updates

Femasys Inc. Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc Permanent Birth Control Clinical Trials

Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way?

Femasys Inc. Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Israeli Regulatory Approvals for Femaseed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Inc. Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Inc. Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemSeed® Infertility Treatment

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 17%

Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check

Consensus revenue estimates fall by 40%

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Femasys Inc., Annual General Meeting, Jul 12, 2024

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target increased by 8.1% to US$10.00

New major risk - Financial position

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 13%

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

New major risk - Share price stability

Femasys Inc. Appoints Richard Spector as Chief Commercial Officer

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors

Femasys Inc. Appoints Joshua Silverman as Director

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

New major risk - Revenue and earnings growth

Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

New major risk - Revenue and earnings growth

Femasys Inc. Designates Daniel Currie as its Chief Operating Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women

Femasys Inc. Announces Management Changes

Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada

Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Femasys Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc.'s FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

Consensus EPS estimates fall by 32%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

Femasys Inc. Reports Encouraging Promotional Launch of Femcerv At AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

Femasys Inc. Completes Over 25% of its Targeted Enrollment in its FemaSeed De Novo Trial

Price target decreased to US$7.33

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Provides Strategic Update on FemaSeed Pivotal Trial Design to Expedite Clinical Program Advancement

Femasys Inc. Appoints Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs, Effective October 10, 2022

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

Femasys Inc. Announces Commercial Availability of FemCerv®

Femasys commercially launches Femcerv for cervical cancer screening

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Femasys Inc. Announces Board Changes

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Femasys Inc. Appoints Dov Elefant to Chief Financial Officer, Effective February 28, 2022

Insufficient new directors